Navigation Links
Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIG's Plenary Panel in Vegas

NEW YORK, Sept. 17 /PRNewswire/ -- iiBIG's New Directions for Drug Delivery: Emerging Modes, Novel Science and Profitable Deal Strategies conference is scheduled for October 29-30, 2007, at the Flamingo in Las Vegas, Nevada. The sessions will cover developments in controlled release technologies, nanobiomedicine, siRNa, protein delivery platforms, liposome drug delivery, tumor targeting and other novel applications for oral/nasal/transdermal/injectable and other systemic drug absorption platforms.

The program agenda will feature 2 tracks focusing on cutting-edge science and new technologies and licensing and commercialization strategies. A sampling of topics includes:

-- Future Advances and Developments in Drug Delivery Nanotechnology

-- Deal Structuring Strategies - University Technology Licensing and


-- The History of Controlled Release Systems from the 1960s to the

Present, and their Evolution from Macro to Micro to Nano Scale DDS

-- Combination Products Delivering Insulin

-- Matrix Effects on Monoclonal Antibodies

-- Sustained Delivery of Drugs with DepoFoam(R) Multivesicular Liposomes

-- FDA Patents - Case Study of Transdermal Patches

-- Advances in Oral Delivery Strategies for Vaccines

-- Transdermal Solutions for Therapeutic Applications- New Science to

Bring to Market

-- Rapid Clinical Evaluation of Drug Delivery Technologies

-- Innovation and Success Strategies - Learning and Un-learning from key


For complete agenda details, visit:

An impressive list of chief scientific officers, principal scientists and savvy business development and deal-making experts from a number of biotechnology, drug delivery and specialty pharmaceutical companies are scheduled to present. They include:

-- Erkki Ruoslahti, MD, PhD, Distinguished Professor, Burnham Institute

for Medical Research (at UCSB)

-- Allan S. Hoffman, Professor of Bioengineering, University of

Washington, College of Engineering

-- John S. Patton, PhD, Founder and Chief Scientific Officer, Nektar


-- Igor Gonda, PhD, Chief Executive Officer, Aradigm Corporation

-- Tomas Landh, Principal Scientist, Preformulation & Delivery, Novo


-- Chris Rhodes, Executive Director Pharmaceutical Sciences, Amylin

-- Mark Tracy, Senior Director, Pharmaceutical Operations, Alnylam

-- Bill van Antwerp, Distinguished Scientist and Chief Technology

Officer, Medtronic

-- Gregory I. Frost, PhD, Vice President and Chief Scientific Officer,

Halozyme Therapeutics

-- Seth Feuerstein, President & CEO, Carigent Therapeutics

-- Khursheed Anwer, PhD, Vice President, Research, Expression Genetics

-- Ravi Kiron, PhD, Chief Operating Officer, LifeTech Innovations

-- Maggie Pax, Senior Director, Business Development, MicroCHIPS

-- Michael Arenberg, Executive Director, Business Development, Durect

-- Fernando Alvarez-Nunez, PhD, Principal Scientist, Small Molecule

Pharmaceutics, Amgen

-- Ashutosh Sharma, PhD, Executive Vice President, Vyteris

-- William Edelman, Chief Executive Officer, TyRx Pharma, Inc.

-- Eric Fossel, PhD, Founder & CEO, Strategic Science & Technologies LLC

-- Bill Lambert, PhD, Senior Vice President, Pharmaceutical Development,

Pacira Pharmaceuticals

-- Aaron F. Barkoff, Partner, McDonnell Boehnen Hulbert & Berghoff LLP

-- David Lechuga-Ballesteros, PhD, Senior Director, R&D, Aridis


-- Peter Scholes, Vice President Pharmaceutical Sciences, Pharmaceutical

Profiles Ltd

-- Mahesh V. Chaubal, PhD, M.S., Director Global R&D, Baxter


-- Jonathan Rigby, Vice President Marketing, Zoegenix Inc.

TECHNOLOGY SHOWCASE PANEL: If your company provides products or services to drug delivery executives and you would like to schedule a 10-15 minute presentation, showcasing opportunities are available. Contact: Kellie Swanstrom, VP, Business Development, iiBIG 973-571-0867 or


Please visit:

Call: 212-300-2523


Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. CIO Leadership Series: Kathi Christian, QTI Group
2. Just in time for Christmas: Retail IT.
3. Musicnotes signs licensing deal with Christian music provider
4. Carl Christensen says Marshfield Clinics history gives it an IT edge
5. An early Christmas gift
6. Christmas comes early with Treo 650
7. Nettles Names Christenson as Director of Bureau of Entrepreneurship
8. Speaker announces business members of IT Task Force
9. Eight lawmakers named to Speakers IT task force
10. What do CIOs want? Fusion2007 speakers weigh in
11. Innovation expert speaks on the business-IT balancing act
Post Your Comments:
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... on behalf of the Toronto Stock Exchange, confirms that ... are no corporate developments that would cause the recent ... --> --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical ...
Breaking Biology Technology:
(Date:11/18/2015)... , November 18, 2015 ... has published a new market report titled  Gesture Recognition ... and Forecast, 2015 - 2021. According to the report, the global ... and is anticipated to reach US$29.1 bn by 2021, ... North America dominated the ...
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
Breaking Biology News(10 mins):